You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Pembrolizumab for advanced melanoma not previously treated with ipilimumab

  • Technology appraisal guidance
  • Reference number: TA366
  • Published:  25 November 2015
  • Last updated:  12 September 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Invitation to participate
  2. Final appraisal determination
  3. Final scope
  4. Final matrix
  5. NICE response to comments on the draft scope and provisional matrix
  6. Equality impact assessment - scoping
  7. Draft scope for consultation (pre-referral) - July 2014
  8. Provisional matrix (pre-referral) - July 2014

History

A list of downloadable documents created during development.

Invitation to participate

  • Equality Impact Assessment (Guidance development) (PDF 155 KB)

    Published:
    26 November 2015

Final appraisal determination

  • Final appraisal determination

  • Appraisal consultation document Final appraisal determination document (PDF 384 KB)

    Published:
    09 October 2015
  • Committee papers (PDF 8.28 MB)

    Published:
    09 October 2015

Final scope

  • Final scope (PDF 99 KB)

    Published:
    08 May 2015

Final matrix

  • Final matrix (PDF 101 KB)

    Published:
    08 May 2015

NICE response to comments on the draft scope and provisional matrix

  • NICE response to comments on the draft scope and provisional matrix (PDF 228 KB)

    Published:
    08 May 2015

Equality impact assessment - scoping

  • Equality impact assessment - scoping (PDF 121 KB)

    Published:
    08 May 2015

Draft scope for consultation (pre-referral) - July 2014

  • Draft scope for consultation (pre-referral) - July 2014 (PDF 110 KB)

    Published:
    09 April 2015

Provisional matrix (pre-referral) - July 2014

  • Provisional matrix (pre-referral) - July 2014 (PDF 103 KB)

    Published:
    09 April 2015